Skip to content

Matinas BioPharma Holdings, Inc.

MTNB

CIK 0001582554

← back to feed
Revenue (TTM)
$3.26M
−65.6% YoY Q1 May 2026
Net Income (TTM)
−$10.35M
+57.3% YoY Q1 May 2026
EPS Diluted (TTM)
−$2.06
+59.8% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-224.1%
Q1 May 2026
Net Margin
-318.1%
Q1 May 2026
Free Cash Flow (TTM)
−$14.24M
Q1 May 2026
Cash
$2.4M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
6.41M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings